BRPI0519476A2 - processo para a sÍntese de cefaclor - Google Patents

processo para a sÍntese de cefaclor

Info

Publication number
BRPI0519476A2
BRPI0519476A2 BRPI0519476-8A BRPI0519476A BRPI0519476A2 BR PI0519476 A2 BRPI0519476 A2 BR PI0519476A2 BR PI0519476 A BRPI0519476 A BR PI0519476A BR PI0519476 A2 BRPI0519476 A2 BR PI0519476A2
Authority
BR
Brazil
Prior art keywords
cefaclor
amount
relates
synthesis process
cefachlor
Prior art date
Application number
BRPI0519476-8A
Other languages
English (en)
Inventor
Harold Monro Moody
Dooren Theodorus Johannes Godfried Maria Van
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of BRPI0519476A2 publication Critical patent/BRPI0519476A2/pt
Publication of BRPI0519476B1 publication Critical patent/BRPI0519476B1/pt
Publication of BRPI0519476B8 publication Critical patent/BRPI0519476B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
    • C12P35/04—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin by acylation of the substituent in the 7 position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/58—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3 with a nitrogen atom, which is a member of a hetero ring, attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

PROCESSO PARA A SÍNTESE DE CEFACLOR A presente invenção se refere a um processo para a síntese de cefaclor, processo o qual compreende reação de ácido 7-amino-3-cloro cefalosporânico (7-ACCA) com D-fenilglicina na forma ativada (PGa) na presença de uma enzima em uma mistura de reação para formar cefaclor, em que pelo menos parte do 7-ACCA e/ou PGa é adicionada à mistura de reação durante o curso da reação. A invenção também se refere a uma mistura aquosa compreendendo uma quantidade de cefaclor de > 10% (peso/peso), uma quantidade de ácido 7-amino-3-cloro cefalosporânico de < 2% (peso/peso) e uma quantidade de D-fenilglicina de < 2% (peso/peso) e um processo para a recuperação de cefaclor dessa mistura aquosa. A invenção também se refere ao cefaclor na forma de cristal tendo uma absorbância a 400 nm (A~ 400~) de menos de 0,250.
BRPI0519476A 2004-12-27 2005-12-23 processo para a síntese de cefaclor e processo para obtenção de cefaclor BRPI0519476B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04106999 2004-12-27
EP04106999.8 2004-12-27
PCT/EP2005/057155 WO2006069984A2 (en) 2004-12-27 2005-12-23 Process for the synthesis of cefaclor

Publications (3)

Publication Number Publication Date
BRPI0519476A2 true BRPI0519476A2 (pt) 2009-02-03
BRPI0519476B1 BRPI0519476B1 (pt) 2020-12-22
BRPI0519476B8 BRPI0519476B8 (pt) 2021-05-25

Family

ID=35512770

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519476A BRPI0519476B8 (pt) 2004-12-27 2005-12-23 processo para a síntese de cefaclor e processo para obtenção de cefaclor

Country Status (8)

Country Link
US (1) US8071330B2 (pt)
EP (1) EP1831390B1 (pt)
JP (1) JP5022913B2 (pt)
KR (1) KR101203287B1 (pt)
CN (1) CN101090978B (pt)
BR (1) BRPI0519476B8 (pt)
MX (1) MX2007007937A (pt)
WO (1) WO2006069984A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264904B (zh) * 2008-12-23 2013-10-23 中化帝斯曼制药有限公司荷兰公司 突变体青霉素g酰基转移酶
EP2723882B1 (en) 2011-06-23 2019-05-01 Centrient Pharmaceuticals Netherlands B.V. Process for preparing 3'-thiosubstituted cephalosporins employing a penicillin g acylase
WO2012175587A2 (en) 2011-06-23 2012-12-27 Dsm Sinochem Pharmaceuticals Netherlands B.V. Novel crystalline cefoperazone intermediate
CN102443014B (zh) * 2011-12-29 2014-07-09 上海右手医药科技开发有限公司 3-氯头孢菌素衍生物及其合成方法与在头孢克洛制备中的应用
CN103571907B (zh) * 2013-10-30 2016-01-13 苏州中联化学制药有限公司 一种酶法合成头孢克洛的分离及纯化方法
CN103757085B (zh) * 2013-11-28 2016-06-15 湖南福来格生物技术有限公司 头孢克洛及其合成方法
CN103667418B (zh) * 2013-12-18 2015-03-25 华北制药河北华民药业有限责任公司 高活性β-内酰胺抗生素合成用酶的高通量筛选方法
CN106222230A (zh) * 2016-08-03 2016-12-14 广州白云山医药集团股份有限公司白云山化学制药厂 一种绿色酶法合成头孢克洛的方法
CN107523603B (zh) * 2017-08-04 2020-12-29 长沙凯晓生物科技有限公司 一种酶法制备头孢克洛的方法
CN109266713A (zh) * 2018-11-12 2019-01-25 齐鲁安替制药有限公司 一种适用于工业生产的头孢克洛的制备方法
CN110408670A (zh) * 2019-08-19 2019-11-05 苏州盛达药业有限公司 一种酶催化合成头孢克洛的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1274658B (it) * 1995-02-28 1997-07-18 Acs Dobfar Spa Procedimento enzimatico migliorato per la produzione di penicilline e cefalosporine
WO1998020120A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Mutant penicillin g acylases
NL1007302C2 (nl) * 1997-10-17 1999-04-20 Dsm Nv Werkwijze voor de bereiding van een ß-lactam antibioticum.
EP1456370A2 (en) * 2001-12-27 2004-09-15 DSM IP Assets B.V. Process for the preparation of a beta-lactam antibiotic with mutated penicillin acylase

Also Published As

Publication number Publication date
CN101090978B (zh) 2012-07-04
MX2007007937A (es) 2007-08-21
CN101090978A (zh) 2007-12-19
EP1831390A2 (en) 2007-09-12
WO2006069984A2 (en) 2006-07-06
BRPI0519476B1 (pt) 2020-12-22
US20080050771A1 (en) 2008-02-28
KR101203287B1 (ko) 2012-11-20
JP5022913B2 (ja) 2012-09-12
US8071330B2 (en) 2011-12-06
WO2006069984A3 (en) 2007-04-12
EP1831390B1 (en) 2014-11-19
JP2008525044A (ja) 2008-07-17
BRPI0519476B8 (pt) 2021-05-25
KR20070090042A (ko) 2007-09-04

Similar Documents

Publication Publication Date Title
BRPI0519476A2 (pt) processo para a sÍntese de cefaclor
BR0212775A (pt) Composto de 1,2,4-triazol
CL2008000777A1 (es) Proceso para la purificacion de agua que comprende agregar al agua que se va a purificar carbonato de calcio natural reaccionando en superficie o una suspension acuosa, el cual tiene un ph superior a 6,0 medido a 20 grados celsius; y un compuesto de carbonato de calcio natural
WO2008113838B1 (en) Process for the removal of endocrine disrupting compounds
BR0314770A (pt) Processo para preparar pelo menos um produto de oxidação e/ou amoxidação parcial de propileno
BRPI0403234A (pt) Negro-de-fumo
BR0208461A (pt) Tampão que apresenta ranhuras de forma espiralada
ATE543521T1 (de) Calciumphosphat-zement
BR9802331A (pt) Processo para produzir uma ciclodextrina.
DK1041068T3 (da) Compounds for treating and preventing diabetic complications
BR0116903A (pt) Métodos para produzir dióxido de titanio substancialmente isento de anatásio com a adição de halogeneto de silìcio
BR0214933A (pt) Cristal de bicalutamida e método de produção para o mesmo
BRPI0500480A (pt) processo para a sìntese de (1s)-4,5-dimetóxi- 1-(metilaminometil)-benzociclobutano e sais de adição deste, e aplicação na sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
BR0116573A (pt) Processo de preparação de sìlica precipitada, contendo o alumìnio
TNSN08414A1 (en) Terphenyl derivatives for treatment of alzheimer&#39;s disease
NO20072382L (no) (S)-(-)-1-(4-Fluorisokinolin-5-yl)-sulfonyl-2-metyl-1,4-homopiperazinhydroklorid dihydrat
BR0015202A (pt) Processo para a purificação de uma solução contendo aminoácido por meio de eletrodiálise, e processo integrado para a produção de um aminoácido livre
BR9708233A (pt) Processo para sìntese de um composto e composto.
BR0211652A (pt) Processo para produção de composto de piridina
BRPI0513517A (pt) processo para a purificação de correntes de gás de co2
DE69840035D1 (de) Chimäres protein welches eine intramolekulare chap zur insulinproduktion
BR0003852A (pt) Pomada nasal a base de petrolato
BRPI0607265A2 (pt) processo para produção de soluções de hidróxido de césio
WO2008055989A3 (fr) Procede de preparation d&#39;alcoxy et/ou halogenosilanes (poly)sulfures, nouveaux produits susceptibles d&#39;etre obtenus par ce procede et application comme agents de couplage
BRPI0412302A (pt) processo para a preparação de cefradina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: CENTRIENT PHARMACEUTICALS NETHERLANDS B.V. (NL)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: CENTRIENT PHARMACEUTICALS NETHERLANDS B.V. (NL)

Free format text: RETIFICACAO DO DESPACHO (25.4) ? ALTERACAO DE NOME PUBLICADO NA RPI NO 2636, DE 13/07/2021, QUANTO AO NOME DO DEPOSITANTE NA AVERBACAO.ONDE SE LE: CENTRIENT PHARMACEUTICALS NETHERLANDS B.VLEIA-SE: CENTRIENT PHARMACEUTICALS NETHERLANDS B.V.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2806 DE 15-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.